Cargando…

Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies

This retrospective study evaluated the benefit of following different long-acting injectable (LAI) initiation strategies based on the timing of behavioral and clinical events among Medicaid beneficiaries with schizophrenia. Adults with schizophrenia initiating oral antipsychotics (OAPs) after 12 mon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Correll, Christoph U., Benson, Carmela, Emond, Bruno, Patel, Charmi, Lafeuille, Marie-Hélène, Lin, Dee, Morrison, Laura, Ghelerter, Isabelle, Lefebvre, Patrick, Mavros, Panagiotis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922270/ https://www.ncbi.nlm.nih.gov/pubmed/36774362 http://dx.doi.org/10.1038/s41537-023-00334-3

Ejemplares similares

Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis
por: Lin, Dee, et al.
Publicado: (2021)

Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate
por: Morrison, Laura, et al.
Publicado: (2023)

Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic
por: Pilon, Dominic, et al.
Publicado: (2017)

A Cross-Sectional Study of Patient Out-of-Pocket Costs for Antipsychotics Among Medicaid Beneficiaries with Schizophrenia
por: Lin, Dee, et al.
Publicado: (2023)

Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis
por: Vanderpoel, Julie, et al.
Publicado: (2023)

Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia
por: Basu, Anirban, et al.
Publicado: (2023)

Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics
por: Pilon, Dominic, et al.
Publicado: (2021)

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
por: Patel, Charmi, et al.
Publicado: (2019)

Racial and Ethnic Disparities in Long-Acting Injectable Antipsychotic Use in a National Sample of Medicare Beneficiaries With Schizophrenia
por: Li, Pengxiang, et al.
Publicado: (2023)

Rapid Initiation of Antiretroviral Therapy Following Diagnosis of Human Immunodeficiency Virus Among Patients with Commercial Insurance Coverage
por: Benson, Carmela, et al.
Publicado: (2020)

Patient-psychiatrist discordance and drivers of prescribing long-acting injectable antipsychotics for schizophrenia management in the real-world: a point-in-time survey
por: Keenan, Alexander, et al.
Publicado: (2022)

Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
por: ATRASH, Shebli, et al.
Publicado: (2021)

Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis
por: Lafeuille, Marie-Hélène, et al.
Publicado: (2013)

Correction to: Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
por: Atrash, Shebli, et al.
Publicado: (2021)

Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
por: El Khoury, Antoine C, et al.
Publicado: (2021)

Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics
por: Correll, Christoph U., et al.
Publicado: (2022)

Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia
por: Fu, Alex Z., et al.
Publicado: (2022)

Health care resource utilization and costs in patients receiving long-acting injectable vs oral antipsychotics: A comparative analysis from the Disease Recovery Evaluation and Modification (DREaM) study
por: Basu, Anirban, et al.
Publicado: (2022)

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
por: Correll, Christoph U., et al.
Publicado: (2021)

The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia
por: Milz, Ruth, et al.
Publicado: (2023)

Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
por: Kane, John M., et al.
Publicado: (2021)

Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate
por: Emond, Bruno, et al.
Publicado: (2018)

Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with Schizophrenia
por: Basu, Anirban, et al.
Publicado: (2018)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2
por: Sajatovic, Martha, et al.
Publicado: (2018)

Real-world analysis of insurance churn among young adults with schizophrenia using the Colorado All-Payer Claims Database
por: Pesa, Jacqueline, et al.
Publicado: (2022)

1460. Respiratory Syncytial Virus (RSV)-Related Clinical Events among a Medicare-Insured Population in the United States
por: DeMartino, Jessica K K, et al.
Publicado: (2022)

Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs
por: Bossie, Cynthia A., et al.
Publicado: (2015)

Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study
por: Emond, Bruno, et al.
Publicado: (2021)

The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System: A Retrospective Mirror-Image Study
por: Mahabaleshwarkar, Rohan, et al.
Publicado: (2021)

Real-World Analysis of Weight Gain and Body Mass Index Increase Among Patients with HIV-1 Using Antiretroviral Regimen Containing Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Neither in the United States
por: Emond, Bruno, et al.
Publicado: (2022)

Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review
por: Coles, Alexandria S., et al.
Publicado: (2021)

Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation
por: Dickson, Matthew C., et al.
Publicado: (2022)

Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM
por: Litman, Robert, et al.
Publicado: (2023)

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
por: Miyamoto, Seiya, et al.
Publicado: (2017)

A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection
por: Atkins, Susan, et al.
Publicado: (2014)

Treatment Patterns and Predictors of Adherence in HIV Patients Receiving Single- or Multiple-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide
por: Chow, Wing, et al.
Publicado: (2020)

Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices
por: Sheffield, Brandon S., et al.
Publicado: (2023)

Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia
por: Lu, Xiaoxiao, et al.
Publicado: (2023)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_tigen62njg6v3uv2k4ojv7kn2q